Abstract BR regimen was a common treatment for elderly patients with mantle cell lymphoma, however, infection and treatment tolerability remain a clinical challenges for those eldly MCL patients. We investigated the application of reduced-dose Bendamustine Combined with Rituximab and Zanubrutinib to provide the treatment evidence for clinical practice. This was a retrospective analysis and all patients receive Bendamustine (70 mg/m2,d1-2) , Rituximab(375mg/m2,d1) and Zanubrutinib (160mg bid) for 6 cycles, every 28 days as a cycle. If the treatment is effective, patients receive Zanubrutinib (160mg bid) for at least 2 years as maintenance therapy. Minimal residual disease was assessed by NGS in blood, and immunological function assessment was performed. A total of 23 patients have been enrolled as of July 2025. Among them, The median age was 68.0 years, with a male predominance (68.2%). Blastoid morphology was observed in 21.7% of cases. The Ki-67 index was ≥30% in 73.9% of patients, and advanced disease stages (IVA and IVB) accounted for 91.3% of cases. The MIPI risk categories were evenly distributed, with 34.8% each in high and intermediate risk groups. 26.1% patients had TP53 aberration and 17.4% were complex karyotype. The complete response rate at 6 course was 73.9% and the overall response rate was 91.3%. As of the follow-up through July 2025, the median progression-free survival (PFS) was is NA 25 - NA, 95% CI months, and the median overall survival (OS) was not reached. The 24-month PFS and OS rates were 75.4% 59%-96.8%, 95% CIand 90.7% 79.2%-100%, 95% CI. Among 16 patients evaluable for MRD, the undetectable MRD (uMRD) rate was 88% (14/16) in the end-of-induction therapy. After six cycles of zanubrutinib maintenance therapy, the uMRD rate increased to 94% (15/16) in the evaluable cohort. Furthermore, longitudinal monitoring of five patients with available serial samples demonstrated sustained MRD negativity at 24 months post-maintenance initiation. Immune function monitoring showed a significant decline in CD4⁺ T-cell and NK-cell counts after three induction cycles, with both reaching their nadir by the end of induction therapy. After 6 months of maintenance treatment, the above indicators began to gradually rebound and 12 months of maintenance treatment, the vast majority of patients' CD4 ⁺ T cells recover to ≥ 200 cells/μ L, and NK cells also return to the normal range. Despite dose reduation, the most frequent treatment-emergent adverse events (TEAEs) were hematological toxicities, with leukopenia occurring in 65.2% of patients (grade ≥3: 34.8%) and thrombocytopenia in 34.8% (grade ≥3: 17.4%). Infectious complications included COVID-19 (13.0% all-grade; fatal in 4.3%) and lung infections (13.0% all-grade; grade ≥3: 8.7%). Conclusions Our results provide preliminary evidence that Zanubrutinib combined reduced-dose Bendamustine with Rituximab plus Zanubrutinib maintenance therapy is an active regimen for eldly MCL, which provides an additional treatment option for clinical practice.
Chuan‐Yuan Li (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: